Emergent BioSolutions and Temasek Life Sciences Ventures Establish JV to Develop Pandemic Flu Vaccine & Therapeutic
Posted on 08/13/2010
According to a press release, “Temasek Life Science Ventures Pte Ltd (TLV) and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains. The broad spectrum pandemic flu vaccine is expected to be based on multiple antigens held by TLV and to be delivered as a single vaccine using Emergent’s MVAtorTM vaccine delivery platform. Completion of this joint venture is expected in the next few weeks.”
Read more: Emergent Biosolutions Press Press Release
Keywords: Temasek Holdings.
